Pasar al contenido principal

ALTERACIONES DEL CONTROL EPIGENETICO DEL DESARROLLO EN ENFERMEDADES RARAS Y LEUCEMIA

PID2021-122787OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

First presence of Macaca sylvanus at the late Early Pleistocene of Barranc de la Boella (La Mina locality, Francolí Basin, NE Iberia)

  • Fidalgo, Darío
  • Rosas, Antonio
  • Estalrrich, Almudena
  • García-Tabernero, Antonio
  • Pastor, Francisco J.
  • Pineda, Antonio
  • Cáceres, Isabel
  • Ollé, Andreu
  • Vallverdú, Josep
  • Saladie, Palmira
The BB specimen is an upper right canine belonging to a male of the primate M. sylvanus. The agreement among the qualitative characteristics of the tooth and the chronology of the site suggest its identification as M. sylvanus cf. florentina, although the lack of consensus on the validity of the proposed subspecies and the large biometric overlap do not allow certainty of this subspecific assignment. Macaca cf. sylvanus fossils are known across Iberia and throughout Europe in the Pliocene and Pleistocene, mainly in warmer intervals. Data suggest that the species is limited to areas that are more southern in colder phases, whereas in warm phases, this taxon could extend its distribution further north. Predation by carnivore species is likely, while interaction with early humans is less definite., This research has been funded by Ministerio de Ciencia e Innovacion, PID2021-122356NB-I00. D.F. is supported by the Ayuda del Programa de Formacion de Profesorado Universitario (FPU20/03389) and is a Ph.D. student at the Programa de Doctorado en Biología at the Universidad Complutense de Madrid. A.E. is supported by H2020-MSCA-IF project No. 891529 (3DFOSSILDIET). A.P. is supported by the LATEUROPE project (Grantagreement ID 101052653) that has received funding from the European Research Council (ERC) under the European Union’s HORIZON1.1 research program. The Barranc de la Boella fieldwork is supported by the Ajuntament de la Canonja and Departament de Cultura of Generalitat de Catalunya (ARQ001SOL-186-2022). The Institut Catala de Paleoecologia Humana i Evoluci o Social (IPHES- CERCA) has received financial support from the Spanish Ministry of Science and Innovation through the ‘María de Maeztu’ program for Units of Excellence (CEX2019-000945-M)., With funding from the Spanish government through the "Severo Ochoa Center of Excellence" accreditation (CEX2019-000945-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An archaeostratigraphic consideration of the Gran Dolina TD10.2 cultural sequence from a quantitative approach

  • Arteaga-Brieba, Andion
  • Courtenay, Lloyd A.
  • Cobo-Sánchez, Lucía
  • Rodríguez-Hidalgo, Antonio
  • Saladié, Palmira
  • Ollé, Andreu
  • Mosquera, Marina
Understanding the temporal resolution of archaeological deposits is a critical issue for drawing behavioural inferences. In the case of TD10.2 (Gran Dolina, Sierra de Atapuerca), this factor becomes essential in defining the mass communal bison hunting level and the different butchering events that took place at the sub-unit, which is characterised as a kill-butchering site. Traditionally, the dissection of events within an assemblage is performed by visual archaeostratigraphic techniques. This method, however, can be challenging in high-density sites without marked sterile gaps between levels. In this study, we present a combination of archaeostratigraphic techniques, supervised machine learning, and lithic refits applied to TD10.2. This integration of techniques offers a more automated and time-efficient archaeostratigraphic analysis, supports a more quantitative strand of evidence, and enables final verification using refits, even though it still requires prior visual archaeostratigraphic processing to set up qualitative data. Results have allowed for the definition of three distinct levels within the sub-unit along the entire excavation surface, highlighting the potential of these methods. Moreover, this approach facilitates the accurate delineation of level boundaries in the bison bone bed level, assessing its high spatiotemporal resolution, and identifying a minimum of two seasonal communal hunting events. This result reinforces previous interpretations while also providing new insights into the subsistence and behavioural strategies of the hominins that occupied the cavity, This research has been developed within the frame of the projects PID2021-122355NBC32 (MICINN-FEDER), SGR 2021-01239 (AGAUR) and 2022PFRURV-64 (URV). A. Arteaga-Brieba is the beneficiary of a predoctoral fellowship from Gobierno de Navarra/Nafarroako Gobernua. L.A. Courtenay is funded by the Spanish Ministry of Science, Innovation and Universities, with an FPI Predoctoral Grant (Ref. PRE 2019-089411), associated with the project RTI 2018-099850-B-I00 and the University of Salamanca. A. Rodríguez-Hidalgo is supported by the Spanish Ministry of Science and Innovation through the “María de Maeztu” (CEX2019-000945-M).Institut Catal a de Paleoecologia Humana i Evolucio Social (IPHES-CERCA) has received financial support from the Spanish Ministry of Science and Innovation through the “María de Maeztu” program for Units of Excellence (CEX 2019-000945-M)., With funding from the Spanish government through the "Severo Ochoa Center of Excellence" accreditation (CEX2019-000945-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proof-of-principle: targeted childhood leukemia prevention

  • Cobaleda, César
  • Ramírez-Orellana, Manuel
  • Vicente-Dueñas, Carolina
  • Weiss, Andreas
  • Nichols, Kim E.
  • Sánchez-García, Isidro
Cancer is the most common cause of disease-related childhood mortality in developed countries, with B-cell acute lymphoblastic leukemia (B-ALL) representing the most frequent. A salient characteristic underlying some cases of childhood B-ALL is the presence of congenital mutations (either inherited or de novo) that are compatible with normal lymphocyte development, but lead to the appearance of a silent population of preleukemic cells that acquire additional genetic mutations and ultimately progress to full-blown B-ALL. The precise mechanisms underlying malignant transformation have been difficult to ascertain due to their development in otherwise healthy-appearing children. Notably, several decades ago, delayed exposure to common infections was postulated as a triggering factor leading to the appearance of the secondary genetic lesions required for B-ALL to develop [1]., Research at C. Cobaleda’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project “PI22/00379 and by a “Miguel Servet Grant” [CPII19/00024 - AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) “A way to make Europe”/”Investing in your future”]. Kim Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the National Cancer Institute Research in ISG group is partially supported by FEDER and by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, and CSI144P20). M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NSD2 as a Promising Target in Hematological Disorders

  • Azagra, Alba
  • Cobaleda, César
Alterations of the epigenetic machinery are critically involved in cancer development and maintenance; therefore, the proteins in charge of the generation of epigenetic modifications are being actively studied as potential targets for anticancer therapies. A very important and widespread epigenetic mark is the dimethylation of Histone 3 in Lysine 36 (H3K36me2). Until recently, it was considered as merely an intermediate towards the generation of the trimethylated form, but recent data support a more specific role in many aspects of genome regulation. H3K36 dimethylation is mainly carried out by proteins of the Nuclear SET Domain (NSD) family, among which NSD2 is one of the most relevant members with a key role in normal hematopoietic development. Consequently, NSD2 is frequently altered in several types of tumors—especially in hematological malignancies. Herein, we discuss the role of NSD2 in these pathological processes, and we review the most recent findings in the development of new compounds aimed against the oncogenic forms of this novel anticancer candidate., Research at C.C.’s laboratory was partially supported by the Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC), and by a Research Contract with the Fundación Síndrome de Wolf–Hirschhorn o 4p-. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged. The C.C. laboratory was member of the EU COST Action LEGEND (CA16223).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Childhood B cell leukemia: Intercepting the paths to progression

  • Cobaleda, Cesar
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez García, Isidro
B-cell Acute Lymphoblastic Leukemia (B-ALL) is the most common pediatric cancer, arising most often in children aged 2–5 years. This distinctive age distribution hints at an association between B-ALL development and disrupted immune system function during a susceptible period during childhood, possibly triggered by early exposure to infection. While cure rates for childhood B-ALL surpass 90% in high-income nations, survivors suffer from diminished quality of life due to the side effects of treatment. Consequently, understanding the origins and evolution of B-ALL, and how to prevent this prevalent childhood cancer, is paramount to alleviate this substantial health burden. This article provides an overview of our current understanding of the etiology of childhood B-ALL and explores how this knowledge can inform preventive strategies., PID2021-122787OB-I00/Ministerio de Ciencia e Innovación/AEI/FEDER Fundación Ramón Areces Banco de Santander PI22/00379/Instituto de Salud Carlos III (ISCIII)/ FEDER European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF))
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
[Data Availability Statement] The data presented in this study are openly available in to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code. Preprints ID: https://doi.org/10.20944/preprints202505.0386.v1., [Data and Code Availability] Authors confirm that all relevant data are included in the paper and/or its supplemental information files. All data reported in this article are deposited to NCBI’s Sequence Read Archive (SRA) under the BioProject accession number PRJNA1084753. This paper does not report original code., [Background/Objectives:] In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms., [Methods and Results:] Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL., [Conclusions:] These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., This research was funded by: Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-“. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20 and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC) and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066–REACTION Project. A. Casado-García was supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by an FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

PD-1 Expression Promotes Immune Evasion in B-ALL

  • Casado-García, Ana
  • García-Aguilera, Gonzalo
  • Pozo, Julio
  • Oak, Ninad
  • Barrena, Susana
  • Ruiz-Corzo, Belén
  • Lalchandani, Jaanam
  • Chamorro-Vera, Ana
  • Castillo-Robleda, Ana
  • Soriano, Beatriz
  • Alemán-Arteaga, Silvia
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • López-Álvarez de Neyra, Andrea
  • Somoza-Cotillas, Paula
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Orfao, Alberto
  • Ramírez‑Orellana, Manuel
  • Sánchez García, Isidro
In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often by unknown mechanisms. Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis but in the absence of PD-1, tumor cells express NK cell inhibitory receptors highlighting the necessity for leukemic cells to evade the host's NK immune response in order to exit the bone marrow. PD-1 expression reduces natural anti-tumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefit by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL., The authors thank all the members of their laboratories for discussion. We also thank the Public Resource of Patient-derived and Expanded Leukemias (PROPEL), https://propel.stjude.cloud, as provider of leukemia xenografts used in this study and the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital. Research at C. Cobaleda's laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and by “ERDF/EU”, and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). K. E. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC); R01CA241452 from the National Cancer Institute; R21AI113490 from the National Institute of Allergy and Infectious Diseases; Histiocytosis Association; and Cures within Reach. MR research is partially supported by Asociación Pablo Ugarte. Research in ISG group is partially supported by Grant PID2021-122185OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and PID2024-155590OB-I00 and by “ERDF/EU”, by Junta de Castilla y León (UIC-017, CSI144P20, and CSI016P23), by the Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC), and by Instituto de Salud Carlos III (ISCIII) (AC24/00021). C. Cobaleda, M. Ramírez, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC), and by the Fundacion Unoentrecienmil (CUNINA project). M. Ramírez, and I. Sánchez-García have been supported by the TRANSCAN2023-1858-066 – REACTION Project. A. Casado-García was supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship (CSI067-18) and by Juan de la Cierva 2022 (JDC2022-049078-I). B. Ruiz-Corzo is supported by a FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship (CSI002-22). S. Alemán-Arteaga and A. Lopez-Alvarez de Neyra are supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887) and (PRE2022-103628), respectively. J. Martínez-Cano was supported by a predoctoral fellowship FPI-UAM 2019. We also thank the Hartwell Center and Dr. Ti-Cheng Chang from the Center for Bioinformatics at SJCRH for their support to the whole genome sequencing and bioinformatic pipelines., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells

  • Ruiz-Corzo, Belén
  • Casado-García, Ana
  • Oak, Ninad
  • Somoza-Cotillas, Paula
  • López-Álvarez de Neyra, Andrea
  • Martínez-Cano, Jorge
  • Pérez-Pons, Alba
  • Sánchez, Elena G.
  • Blanco, Oscar
  • Blanco, Oscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Orfao, Alberto
  • Ramírez-Orellana, Manuel
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez-García, Isidro
The contribution of 9p deletion to B cell acute lymphoblastic leukemia (B-ALL) has remained elusive since its discovery more than 40 years ago. Here we show that loss of CD72 is recurrent in B-ALL cases containing PAX5 deletions, and that Cd72 haploinsufficiency drives B-ALL development in Pax5+/- mice. Mechanistically, Cd72+/-;Pax5+/- precursor B cells exhibited an inflammatory transcriptional profile characterized by a decrease in Myd88 expression, a finding that aligns with our previous studies of B-ALL development in Pax5+/- mice following exposure to immune stressors. These combined genomic analyses and functional models provide compelling evidence that co-deletion of 2 contiguous genes, Pax5 and Cd72, drives B cell leukemogenesis., MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grants PID2021-122185OB-I00 and PID2024-155590OB-I00 (to ISG). Junta de Castilla y León grants UIC-017, CSI144P20, and CSI016P23 (to ISG). Fundacion Unoentrecienmil CUNINA2 project (to ISG). Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) (to ISG). Instituto de Salud Carlos III (ISCIII) (AC24/00021) (to ISG). Fundación Científica de la Asociación Española contra el Cáncer grant PRYCO211305SANC (to CC, MR, and ISG). “La Caixa” Foundation under the project code LCF/PR/HR25/52450048 (to CC, MR, and ISG). TRANSCAN2023-1858-066 – REACTION Project (to MR and ISG). Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grant PID2021-122787OB-I00 (to CC). “Fundación Síndrome de Wolf-Hirschhorn o 4p-” research contract (to CC). “Fundación Ramón Areces” and “Banco de Santander” institutional grants to the Centro de Biología Molecular. Instituto de Salud Carlos III (ISCIII) project PI22/00379 (to CVD). American Lebanese Syrian Associated Charities (ALSAC) (to KEN). National Cancer Institute/NIH grant R01CA241452 (to KEN). National Institute of Allergy and Infectious Diseases Histiocytosis Association Cures within Reach grant R21AI113490 (to KEN). Asociación Pablo Ugarte (to MR). FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship CSI067-18 (to ACG). Juan de la Cierva 2022 grant JDC2022-049078-I (to ACG). FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship CSI002-22 (to BRC). Ayuda para Contratos predoctorales para la formación de doctores (PRE2022-103628) (to ALAN). Universidad Autónoma de Madrid predoctoral fellowship FPI-UAM 2019 (to JMC).